Arthur S. Waldbaum

Obstetrics and Gynecology

3773 E Cherry Creek North Dr Ste 685
Denver, CO 80209

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

A phase 3, randomized, controlled trial of Astodrimer 1% Gel for preventing recurrent bacterial vaginosis.

A phase 3, randomized, controlled trial of Astodrimer 1% Gel for preventing recurrent bacterial vaginosis.

Journal: European journal of obstetrics & gynecology and reproductive biology: X

Published: September 30, 2020

Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).

Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).

Journal: Menopause (New York, N.Y.)

Published: August 10, 2020

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.

Journal: Menopause (New York, N.Y.)

Published: February 27, 2020

Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis.

Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis.

Journal: European journal of obstetrics, gynecology, and reproductive biology

Published: August 05, 2019

A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis.

A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis.

Journal: PloS one

Published: July 15, 2019

Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.

Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.

Journal: Menopause (New York, N.Y.)

Published: January 30, 2019

Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial.

Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial.

Journal: Obstetrics and gynecology

Published: July 12, 2017

Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.

Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.

Journal: Climacteric : the journal of the International Menopause Society

Published: December 17, 2014

Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.

Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.

Journal: Maturitas

Published: November 27, 2014

Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a dose-ranging study.

Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a dose-ranging study.

Journal: Journal of lower genital tract disease

Published: July 02, 2014

Tranexamic acid increases hemoglobin and ferritin levels in women with heavy menstrual bleeding.

Tranexamic acid increases hemoglobin and ferritin levels in women with heavy menstrual bleeding.

Journal: Journal of women's health (2002)

Published: March 21, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026